Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Outcome of children and adolescents with central nervous system tumors in phase I trials.

Carceller F, Bautista F, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Vassal G, Pearson ADJ, Geoerger B, Moreno L, Marshall LV.

J Neurooncol. 2018 Mar;137(1):83-92. doi: 10.1007/s11060-017-2698-z. Epub 2017 Dec 13.

PMID:
29236237
2.

Genotoxic Damage Activates the AMPK-α1 Isoform in the Nucleus via Ca2+/CaMKK2 Signaling to Enhance Tumor Cell Survival.

Vara-Ciruelos D, Dandapani M, Gray A, Egbani EO, Evans AM, Hardie DG.

Mol Cancer Res. 2018 Feb;16(2):345-357. doi: 10.1158/1541-7786.MCR-17-0323. Epub 2017 Nov 13.

PMID:
29133590
3.

Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.

Vardon A, Dandapani M, Cheng D, Cheng P, De Santo C, Mussai F.

Oncotarget. 2017 Jun 29;8(38):63506-63517. doi: 10.18632/oncotarget.18843. eCollection 2017 Sep 8.

4.

Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.

Carceller F, Bautista FJ, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Marshall LV, Vassal G, Pearson AD, Geoerger B, Moreno L.

Eur J Cancer. 2016 Nov;67:130-140. doi: 10.1016/j.ejca.2016.08.008. Epub 2016 Sep 21.

PMID:
27662616
5.

The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CNS) tumours: protocol for a systematic review.

Main C, Dandapani M, Pritchard M, Dodds R, Stevens SP, Thorp N, Taylor RE, Wheatley K, Pizer B, Morrall M, Phillips R, English M, Kearns PR, Wilne S, Wilson JS.

Syst Rev. 2016 Jul 27;5(1):124. doi: 10.1186/s13643-016-0285-6. Review.

6.

Wnt Signaling and Survival of Women With High-Grade Serous Ovarian Cancer: A Brief Report.

Seagle BL, Dandapani M, Yeh JY, Shahabi S.

Int J Gynecol Cancer. 2016 Jul;26(6):1078-80. doi: 10.1097/IGC.0000000000000726.

PMID:
27327150
7.

Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer.

Seagle BL, Eng KH, Yeh JY, Dandapani M, Schiller E, Samuelson R, Odunsi K, Shahabi S.

Sci Rep. 2016 Feb 17;6:21591. doi: 10.1038/srep21591.

8.

Delayed and clinically isolated port site carcinosarcoma recurrence as an early indicator of disseminated disease.

Dandapani M, Seagle BL, Chacho MS, Shahabi S.

Gynecol Oncol Rep. 2015 Sep 1;14:12-5. doi: 10.1016/j.gore.2015.08.003. eCollection 2015 Nov.

9.

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.

Seagle BL, Eng KH, Dandapani M, Yeh JY, Odunsi K, Shahabi S.

Oncotarget. 2015 Jul 30;6(21):18641-52.

10.

Metastatic Uterine Leiomyosarcoma Involving Bilateral Ovarian Stroma without Capsular Involvement Implies a Local Route of Hematogenous Dissemination.

Dandapani M, Seagle BL, Abdullah A, Hatfield B, Samuelson R, Shahabi S.

Case Rep Obstet Gynecol. 2015;2015:950373. doi: 10.1155/2015/950373. Epub 2015 May 24.

11.

TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.

Seagle BL, Yang CP, Eng KH, Dandapani M, Odunsi-Akanji O, Goldberg GL, Odunsi K, Horwitz SB, Shahabi S.

Gynecol Oncol. 2015 Jul;138(1):159-64. doi: 10.1016/j.ygyno.2015.04.039. Epub 2015 May 6.

12.

Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.

Everett JN, Raymond VM, Dandapani M, Marvin M, Kohlmann W, Chittenden A, Koeppe E, Gustafson SL, Else T, Fullen DR, Johnson TM, Syngal S, Gruber SB, Stoffel EM.

JAMA Dermatol. 2014 Dec;150(12):1315-21.

13.

Are nurse-conducted brief interventions (NCBIs) efficacious for hazardous or harmful alcohol use? A systematic review.

Joseph J, Basu D, Dandapani M, Krishnan N.

Int Nurs Rev. 2014 Jun;61(2):203-10. doi: 10.1111/inr.12096. Epub 2014 Mar 20. Review.

PMID:
24645911
14.

AMPK: mediating the metabolic effects of salicylate-based drugs?

Steinberg GR, Dandapani M, Hardie DG.

Trends Endocrinol Metab. 2013 Oct;24(10):481-7. doi: 10.1016/j.tem.2013.06.002. Epub 2013 Jul 19.

15.

AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?

Dandapani M, Hardie DG.

Biochem Soc Trans. 2013 Apr;41(2):687-93. doi: 10.1042/BST20120351. Review.

16.

Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome.

Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM.

Gynecol Oncol. 2012 Dec;127(3):544-51. doi: 10.1016/j.ygyno.2012.08.031. Epub 2012 Aug 29.

17.

CLINICAL MANAGEMENT OF FAMILIES WITH HEREDITARY COLORECTAL CANCER SYNDROMES.

Dandapani M, Stoffel EM.

Semin Colon Rectal Surg. 2011 Jun 1;22(2):100-104.

18.

Phlebotomy tips for junior doctors.

Dandapani M, Rajagopalan S.

Br J Hosp Med (Lond). 2006 Nov;67(11):M210-1. Review. No abstract available.

PMID:
17134096
19.

Oxidative damage in intermediate syndrome of acute organophosphorous poisoning.

Dandapani M, Zachariah A, Kavitha MR, Jeyaseelan L, Oommen A.

Indian J Med Res. 2003 Jun;117:253-9.

PMID:
14748471

Supplemental Content

Loading ...
Support Center